Actively Recruiting
Phase 1 Study of ISM6331 Capsules for Advanced or Metastatic Malignant Mesothelioma and Other Solid Tumors Evaluating Safety, Dosage, and Early Effectiveness
Led by InSilico Medicine Hong Kong Limited · Updated on 2026-02-17
100
Participants Needed
10
Research Sites
25 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying ISM6331, an investigational drug, in adults with advanced or metastatic malignant mesothelioma or other solid tumors who have limited treatment options. This Phase 1, open-label, multicenter trial aims to assess the safety, tolerability, recommended dose for further study, how the drug is processed in the body, and early signs of anti-tumor activity. The trial includes two parts dose escalation to find safe dosing levels, and dose selection to optimize treatment dose.
CONDITIONS
Brief Title
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
Research Team
Q
Qinhan Chen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
